Tier 2 — strong
Investigating fucoidan blend supplementation and resistance training in humans: a parallel randomized controlled trial design
Scientific Reports
2025
15(1):40249
Bibliography
- PubMed
- PMID 41249370
- PubMed Central
- PMC12624114
- Trial registry
- View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
- Funding
- Supported by Marinova Pty Ltd, which also produced and supplied the fucoidan blend.
- Competing interests
- The authors declared no competing interests.
Study snapshot
| Design | Six-week randomized double-blind placebo-controlled parallel trial with supervised resistance training |
|---|---|
| Model | Apparently healthy adults completing resistance training |
| Sample | 20 participants (10 fucoidan, 10 placebo) |
| Intervention | 1 g/day fucoidan blend containing Undaria pinnatifida and Fucus vesiculosus versus microcrystalline-cellulose placebo during resistance training |
| Duration | 6 weeks |
| Endpoints | 1RM back squat; Wingate peak power; Lean body mass; Body fat percentage; Blood measures |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- SIRT6, Muscle & Exercise: AMPK, Oxidative Fibers and Human EvidenceSIRT6 supports muscle metabolism, AMPK and oxidative fibers in animal studies. See human exercise associations, activator data and what performance claims remain...Read analysis
- Fucoidan SIRT6 Activator: The Evidence, In Mice and HumansFucoidan is the leading natural SIRT6 activator candidate. Mouse and mechanistic evidence has now progressed into human testing, including NUS PROMETHEUS and...Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
